106 related articles for article (PubMed ID: 27432558)
21. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.
D'Agostino M; Voce P; Celano M; Sponziello M; Moretti S; Maggisano V; Verrienti A; Durante C; Filetti S; Puxeddu E; Russo D
Thyroid; 2012 Feb; 22(2):138-44. PubMed ID: 22191389
[TBL] [Abstract][Full Text] [Related]
22. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
23. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
24. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
[TBL] [Abstract][Full Text] [Related]
26. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Gao J; Jia WD; Li JS; Wang W; Xu GL; Ma JL; Ge YS; Yu JH; Ren WH; Liu WB; Zhang CH
J Int Med Res; 2010; 38(4):1413-27. PubMed ID: 20926014
[TBL] [Abstract][Full Text] [Related]
27. The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer.
Montoya A; Varela-Ramirez A; Dickerson E; Pasquier E; Torabi A; Aguilera R; Nahleh Z; Bryan B
Biomed J; 2019 Jun; 42(3):155-165. PubMed ID: 31466709
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.
Wolter JK; Wolter NE; Blanch A; Partridge T; Cheng L; Morgenstern DA; Podkowa M; Kaplan DR; Irwin MS
Oncotarget; 2014 Jan; 5(1):161-72. PubMed ID: 24389287
[TBL] [Abstract][Full Text] [Related]
29. ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).
Prasetyanti PR; Capone E; Barcaroli D; D'Agostino D; Volpe S; Benfante A; van Hooff S; Iacobelli V; Rossi C; Iacobelli S; Medema JP; De Laurenzi V; Sala G
Oncotarget; 2015 Jul; 6(19):16902-11. PubMed ID: 26160848
[TBL] [Abstract][Full Text] [Related]
30. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells.
Wang F; Liu H; Wang F; Xu R; Wang P; Tang F; Zhang X; Zhu Z; Lv H; Han T
Mol Med Rep; 2018 Apr; 17(4):5213-5221. PubMed ID: 29393410
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
Zubrilov I; Sagi-Assif O; Izraely S; Meshel T; Ben-Menahem S; Ginat R; Pasmanik-Chor M; Nahmias C; Couraud PO; Hoon DS; Witz IP
Cancer Lett; 2015 May; 361(1):86-96. PubMed ID: 25725450
[TBL] [Abstract][Full Text] [Related]
32. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
33. Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner.
Li P; Guo Z; Gao Y; Pan W
Oncol Rep; 2015 Jun; 33(6):3099-107. PubMed ID: 25872592
[TBL] [Abstract][Full Text] [Related]
34. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Liu D; Liu Z; Jiang D; Dackiw AP; Xing M
J Clin Endocrinol Metab; 2007 Dec; 92(12):4686-95. PubMed ID: 17911174
[TBL] [Abstract][Full Text] [Related]
36. beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration.
Işeri OD; Sahin FI; Terzi YK; Yurtcu E; Erdem SR; Sarialioglu F
Pharm Biol; 2014 Nov; 52(11):1374-81. PubMed ID: 25026350
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticles carrying fingolimod and methotrexate enables targeted induction of apoptosis and immobilization of invasive thyroid cancer.
Niemelä E; Desai D; Niemi R; Doroszko M; Özliseli E; Kemppainen K; Rahman NA; Sahlgren C; Törnquist K; Eriksson JE; Rosenholm JM
Eur J Pharm Biopharm; 2020 Mar; 148():1-9. PubMed ID: 31917332
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade.
Choy C; Raytis JL; Smith DD; Duenas M; Neman J; Jandial R; Lew MW
Oncol Rep; 2016 Jun; 35(6):3135-42. PubMed ID: 27035124
[TBL] [Abstract][Full Text] [Related]
39. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
40. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]